Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Takeda to Book One-Time Profit Gains after SHP647 Divestment Obligation Cleared
Takeda Pharmaceutical said on June 22 that it will book one-off gains on profits for the year ending March 2021 in relation to the European Commission’s (EC) decision to clear the company’s obligation to divest Shire’s pipeline compound SHP647. When…
To read the full story
Related Article
- Takeda Ups Full-Year Profit Guidance after EU Clears Obligation to Divest SHP647
August 3, 2020
- Takeda Winds Up Development of IBD Drug SHP647
June 1, 2020
- Takeda Gets European OK for Shire Deal with Strings Attached
November 21, 2018
BUSINESS
- Enflonsia Filed for High-Risk Children in 2nd RSV Season in Japan: MSD
August 17, 2026
- Keytruda Keeps Grip on Top Spot in July Drug Sales: Encise
August 17, 2026
- Japan Ethical Drug Sales Jump 9% in June: Crecon
August 17, 2026
- Chiba Downpours Cause No Major Disruption to Drug Operations
August 17, 2026
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…